HALO News and Press, Halozyme Therapeutics Inc. From 11/11/19

Halozyme Therapeutics ( HALO ) announced that its product PEGPH20 failed to achieve statistical significance in a phase 3 study treating patients with metastatic pancreatic cancer. This was a major setback for the company and its shareholders. However, this move prompted it to move quickly...

Apellis Pharma (NASDAQ: APLS ) initiated with Neutral rating and $33 (8% upside) price target at Credit Suisse. More news on: Apellis Pharmaceuticals, Inc., Aphria Inc., argenx SE, Healthcare stocks news, Stocks on the move, , Consumer stocks news, Read more ...

Citing its intent to focus its resources on it ENHANZE drug delivery technology, Halozyme Therapeutics ( HALO +1.1% ) will terminate development of PEGPH20, shut down its oncology operations and cut 160 jobs representing ~55% of its workforce. Most (~80%) of the layoffs will be done by e...

SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced strategic actions to reposition the Company with a focus solely on its ENHANZE ® drug delivery technology. In order to implement this strategic shift, Halozyme will immediately ...

SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreas cancer failed to reach the pr...

SAN DIEGO , Oct. 21, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the third quarter 2019 on Tuesday, November 12 at 4:30 p.m. ET / ...

SAN DIEGO , Sept. 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 2019 Cantor Global Healthcare Conference in New York, NY .  Dr. Helen Torley , presiden...

A Phase 3 clinical trial, FeDeriCa , evaluating the subcutaneous (SC) administration of a fixed-dose combination of Roche's ( OTCQX:RHHBY ) Herceptin (trastuzumab) and Perjeta (pertuzumab) plus chemo in patients with HER2-positive early-stage breast cancer showed it to be non-inferior to ...

Halozyme Therapeutics (NASDAQ: HALO ) announces that the global phase III FeDeriCa study conducted by Genentech, met its primary endpoint. The study investigated a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) for subcutaneous administration using Halozyme's EN...

SAN DIEGO , Sept. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its ...